SG11201908517XA - Pyrimidinyl-pyridyloxy-naphthyl compounds and methods of treating ire1-related diseases and disorders - Google Patents
Pyrimidinyl-pyridyloxy-naphthyl compounds and methods of treating ire1-related diseases and disordersInfo
- Publication number
- SG11201908517XA SG11201908517XA SG11201908517XA SG11201908517XA SG 11201908517X A SG11201908517X A SG 11201908517XA SG 11201908517X A SG11201908517X A SG 11201908517XA SG 11201908517X A SG11201908517X A SG 11201908517XA
- Authority
- SG
- Singapore
- Prior art keywords
- california
- san francisco
- south san
- international
- dna way
- Prior art date
Links
- -1 Pyrimidinyl-pyridyloxy-naphthyl compounds Chemical class 0.000 title abstract 3
- 208000037765 diseases and disorders Diseases 0.000 title abstract 2
- 101100452784 Caenorhabditis elegans ire-1 gene Proteins 0.000 title 1
- 108020004414 DNA Proteins 0.000 abstract 8
- 102100030013 Endoribonuclease Human genes 0.000 abstract 3
- 108091006081 Inositol-requiring enzyme-1 Proteins 0.000 abstract 3
- 239000003795 chemical substances by application Substances 0.000 abstract 2
- 239000003814 drug Substances 0.000 abstract 2
- 229940000425 combination drug Drugs 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 230000001419 dependent effect Effects 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 102000015694 estrogen receptors Human genes 0.000 abstract 1
- 108010038795 estrogen receptors Proteins 0.000 abstract 1
- 230000006870 function Effects 0.000 abstract 1
- 230000001404 mediated effect Effects 0.000 abstract 1
- 230000008520 organization Effects 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 102220240796 rs553605556 Human genes 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 229940124597 therapeutic agent Drugs 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pyridine Compounds (AREA)
Abstract
DISEASESAND DISORDERS cc kr) ,•\"% h N SD (R ), 0 1-1 O C RA N H R 7 1 (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (43) International Publication Date 20 September 2018 (20.09.2018) WIPO I PCT oimitia °nolo OilIIIII0111IIIIIOH o imio oimIE (10) International Publication Number WO 2018/166528 Al (51) International Patent Classification: CO7D 403/04 (2006.01) A61K 31/445 (2006.01) CO7D 403/14 (2006.01) A61K 31/506 (2006.01) A61K 31/4545 (2006.01) A61P 35/00 (2006.01) (21) International Application Number: PCT/CN2018/079292 (22) International Filing Date: 16 March 2018 (16.03.2018) (25) Filing Language: English (26) Publication Language: English (30) Priority Data: PCT/CN2017/077059 17 March 2017 (17.03.2017) CN (71) Applicants: GENENTECH, INC. [US/US]; 1 DNA Way, South San Francisco, California 94080 (US). THE RE- GENTS OF THE UNIVERSITY OF CALIFORNIA [US/US]; 1111 Franklin Street, Twelfth Floor, Oakland, California 94607 (US). = (72) Inventors; and (71) Applicants (for MN only): BRAUN, Marie-Gabrielle [FR/US]; 1 DNA Way, South San Francisco, California 94080 (US). GIBBONS, Paul [US/US]; 1 DNA Way, South San Francisco, California 94080 (US). LEE, Wendy [US/US]; 1 DNA Way, South San Francisco, California 94080 (US). LY, Cuong [US/US]; 1 DNA Way, South San Francisco, California 94080 (US). RUDOLPH, Joachim [DE/US]; 1 DNA Way, South San Francisco, California 94080 (US). SCHWARZ, Jacob [US/US]; 1 DNA Way, South San Francisco, California 94080 (US). ASHKE- NAZI, Avi [US/US]; 1 DNA Way, South San Francisco, California 94080 (US). FU, Leo [CN/CN]; 288 Fute Zhong Road, Waigaoqiao Free Trade Zone, Shanghai 200131 (CN). LAI, Tommy [CN/CN]; 288 Fute Zhong Road, Waigaoqiao Free Trade Zone, Shanghai 200131 (CN). WANG, Fei [CN/CN]; 288 Fute Zhong Road, Waigaoqiao Free Trade Zone, Shanghai 200131 (CN). BEVERIDGE, Ramsay [CA/CA]; 2525 Avenue Marie-Curie, Montreal, Quebec H4S 2E1 (CA). ZHAO, Liang [CA/CA]; 2525 Av- enue Marie-Curie, Montreal, Quebec H4S 2E1 (CA). (74) Agent: WU, FENG & ZHANG; 3 FL, Building 2, Yard 3, Fengxiuzhonglu Road, Haidian District, Beijing 100094 (CN). (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). Published: — with international search report (Art. 21(3)) (54) Title: PYRIMIDINYL-PYRIDYLOXY-NAPHTHYL COMPOUNDS AND METHODS OF TREATING IRE1-RELATED (57) : Described herein are pyrimidinyl-pyridyloxy-naphthyl compounds with inositol requiring enzyme 1 (IRE1) modulation activity or function having the Formu- la (I) or (I') structure : or stereoisomers, tautomers, or pharmaceutically acceptable salts thereof, and with the substituents and structural features described herein. Also described are pharmaceutical compositions and medicaments that include the Formula (I) or (I') compounds, as well as methods of using such IRE1 modulators, alone and in combina- tion with other therapeutic agents, for treating diseases or conditions that are mediated or dependent upon estrogen receptors.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2017077059 | 2017-03-17 | ||
| PCT/CN2018/079292 WO2018166528A1 (en) | 2017-03-17 | 2018-03-16 | Pyrimidinyl-pyridyloxy-naphthyl compounds and methods of treating ire1-related diseases and disorders |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201908517XA true SG11201908517XA (en) | 2019-10-30 |
Family
ID=63522807
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201908517X SG11201908517XA (en) | 2017-03-17 | 2018-03-16 | Pyrimidinyl-pyridyloxy-naphthyl compounds and methods of treating ire1-related diseases and disorders |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US10968203B2 (en) |
| EP (1) | EP3596063A4 (en) |
| JP (1) | JP6925435B2 (en) |
| KR (1) | KR20190141145A (en) |
| CN (1) | CN111247136A (en) |
| AR (1) | AR111281A1 (en) |
| AU (1) | AU2018233402A1 (en) |
| BR (1) | BR112019019193A2 (en) |
| CA (1) | CA3056833A1 (en) |
| CL (1) | CL2019002671A1 (en) |
| CO (1) | CO2019010078A2 (en) |
| CR (1) | CR20190433A (en) |
| IL (1) | IL269302A (en) |
| PE (1) | PE20191557A1 (en) |
| SG (1) | SG11201908517XA (en) |
| TW (1) | TW201838981A (en) |
| WO (1) | WO2018166528A1 (en) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3597040A4 (en) | 2017-03-17 | 2020-12-09 | Meiji Seika Pharma Co., Ltd. | AGENTS FOR FIGHTING PLANT DISEASES |
| WO2018222918A1 (en) | 2017-06-01 | 2018-12-06 | Quentis Therapeutics, Inc. | Ire1 small molecule inhibitors |
| US10392367B2 (en) | 2017-06-01 | 2019-08-27 | Quentis Therapeutics, Inc. | IRE1 small molecule inhibitors |
| US20210198238A1 (en) * | 2018-08-30 | 2021-07-01 | The Regents Of The University Of California | Ire1 kinase inhibitors and uses thereof |
| CN112689528B (en) * | 2018-09-12 | 2024-05-14 | 基因泰克公司 | Pyrimidinyl-heteroaryloxy-naphthyl compounds and methods of use |
| TWI831829B (en) | 2018-09-12 | 2024-02-11 | 美商建南德克公司 | Phenoxy-pyridyl-pyrimidine compounds and methods of use |
| US11945784B2 (en) | 2018-12-03 | 2024-04-02 | Cornell University | IRE1 small molecule inhibitors |
| SG11202105690TA (en) | 2018-12-03 | 2021-06-29 | Univ Cornell | Ire1 small molecule inhibitors |
| WO2020142612A1 (en) | 2019-01-03 | 2020-07-09 | Genentech, Inc. | Pyrido-pyrimidinone and pteridinone compounds as inhibitors of endoribonuclease inositol requiring enzyme i (ire i alpha) for the treatment of cancer diseases. |
| WO2020232403A1 (en) * | 2019-05-15 | 2020-11-19 | Cornell University | Treatment of fibrosis with ire1 small molecule inhibitors |
| US20230331719A1 (en) * | 2020-08-07 | 2023-10-19 | Optikira, LLC | Pyrazolopyridine Compounds and Methods of Inhibiting IRE1 Using Same |
| KR20230118855A (en) * | 2020-11-13 | 2023-08-14 | 더 리전츠 오브 더 유니버시티 오브 캘리포니아 | IRE1α Inhibitors and Uses Thereof |
| US11840523B2 (en) | 2020-11-13 | 2023-12-12 | The Regents Of The University Of California | IRE1α inhibitors and uses thereof |
| CN114907350B (en) * | 2021-02-10 | 2023-12-29 | 上海凌达生物医药有限公司 | Nitrogen-containing condensed ring compound, preparation method and application |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1751136B1 (en) | 2004-05-07 | 2014-07-02 | Amgen Inc. | Nitrogenated heterocyclic derivatives as protein kinase modulators and use for the treatment of angiogenesis and cancer |
| US7868177B2 (en) * | 2006-02-24 | 2011-01-11 | Amgen Inc. | Multi-cyclic compounds and method of use |
| EP2340248B1 (en) | 2008-09-15 | 2017-05-31 | The Regents of The University of California | Methods and compositions for modulating ire1, src, and abl activity |
| JP6268276B2 (en) | 2013-04-04 | 2018-01-24 | ヤンセン ファーマシューティカ エヌ．ベー． | Novel N (2,3-dihydro-1H-pyrrolo [2,3-b] pyridin-5-yl) -4-quinazolinamine derivatives and N- (2,3-dihydro-1H-indoles as PERK inhibitors -5-yl) -4-quinazolineamine derivatives |
-
2018
- 2018-03-15 AR ARP180100604A patent/AR111281A1/en unknown
- 2018-03-15 TW TW107108924A patent/TW201838981A/en unknown
- 2018-03-16 CR CR20190433A patent/CR20190433A/en unknown
- 2018-03-16 SG SG11201908517X patent/SG11201908517XA/en unknown
- 2018-03-16 BR BR112019019193A patent/BR112019019193A2/en not_active Application Discontinuation
- 2018-03-16 JP JP2019551376A patent/JP6925435B2/en active Active
- 2018-03-16 CA CA3056833A patent/CA3056833A1/en not_active Abandoned
- 2018-03-16 AU AU2018233402A patent/AU2018233402A1/en not_active Abandoned
- 2018-03-16 PE PE2019001893A patent/PE20191557A1/en unknown
- 2018-03-16 EP EP18768363.6A patent/EP3596063A4/en active Pending
- 2018-03-16 KR KR1020197030386A patent/KR20190141145A/en not_active Ceased
- 2018-03-16 CN CN201880032314.6A patent/CN111247136A/en active Pending
- 2018-03-16 WO PCT/CN2018/079292 patent/WO2018166528A1/en active Application Filing
- 2018-05-24 US US15/989,008 patent/US10968203B2/en active Active
-
2019
- 2019-09-12 IL IL26930219A patent/IL269302A/en unknown
- 2019-09-17 CL CL2019002671A patent/CL2019002671A1/en unknown
- 2019-09-18 CO CONC2019/0010078A patent/CO2019010078A2/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| US10968203B2 (en) | 2021-04-06 |
| CN111247136A (en) | 2020-06-05 |
| PE20191557A1 (en) | 2019-10-24 |
| US20180265497A1 (en) | 2018-09-20 |
| TW201838981A (en) | 2018-11-01 |
| JP2020514377A (en) | 2020-05-21 |
| KR20190141145A (en) | 2019-12-23 |
| JP6925435B2 (en) | 2021-08-25 |
| CA3056833A1 (en) | 2018-09-20 |
| AU2018233402A1 (en) | 2019-10-10 |
| WO2018166528A1 (en) | 2018-09-20 |
| CL2019002671A1 (en) | 2019-12-06 |
| EP3596063A1 (en) | 2020-01-22 |
| IL269302A (en) | 2019-11-28 |
| EP3596063A4 (en) | 2020-12-30 |
| CR20190433A (en) | 2019-11-20 |
| CO2019010078A2 (en) | 2020-01-17 |
| BR112019019193A2 (en) | 2020-04-22 |
| AR111281A1 (en) | 2019-06-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG11201908517XA (en) | Pyrimidinyl-pyridyloxy-naphthyl compounds and methods of treating ire1-related diseases and disorders | |
| SG11201811559WA (en) | Cancer treatment combinations | |
| SG11201908330PA (en) | Farnesoid x receptor agonists and uses thereof | |
| SG11201808990QA (en) | Compositions for topical application of compounds | |
| SG11201902938TA (en) | Compounds, devices, and uses thereof | |
| SG11201808237UA (en) | Substituted indole compound derivatives as dengue viral replication inhibitors | |
| SG11201806544XA (en) | Compounds and methods of treating rna-mediated diseases | |
| SG11201809344QA (en) | Process for synthesizing 2-hydroxy-6-((2-(1-isopropyl-1h-pyrazol-5-yl)-pyridin-3-yl)methoxy)benzaldehyde | |
| SG11201900163PA (en) | Macrocycle kinase inhibitors | |
| SG11201900558RA (en) | Spiro-lactam nmda receptor modulators and uses thereof | |
| SG11201908786VA (en) | Substituted indoline derivatives as dengue viral replication inhibitors | |
| SG11201907840RA (en) | Fused imidazo-piperidine jak inhibitors | |
| SG11201811230RA (en) | Compositions and methods for reducing ocular neovascularization | |
| SG11201808270PA (en) | Substituted indoline derivatives as dengue viral replication inhibitors | |
| SG11201807708SA (en) | Estrogen receptor modulators | |
| SG11201808138YA (en) | Substituted indole derivatives as dengue viral replication inhibitors | |
| SG11201900554YA (en) | Spiro-lactam nmda modulators and methods of using same | |
| SG11201900443VA (en) | Spiro-lactam nmda receptor modulators and uses thereof | |
| SG11201908465QA (en) | Substituted indoline derivatives as dengue viral replication inhibitors | |
| SG11201900551WA (en) | Spiro-lactam nmda receptor modulators and uses thereof | |
| SG11201900546UA (en) | Spiro-lactam and bis-spiro-lactam nmda receptor modulators and uses thereof | |
| SG11201810280YA (en) | Spiro-lactam nmda receptor modulators and uses thereof | |
| SG11201907356SA (en) | Piperidine-substituted mnk inhibitors and methods related thereto | |
| SG11201906436VA (en) | Novel heterocyclic compound, its preparation method, and pharmaceutical composition comprising the same | |
| SG11202000333UA (en) | Bicyclic ketone compounds and methods of use thereof |